Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • Vaccine Hub
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
  • Fact Check
  • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Fact Check
      • Bone Health Fact Check
      • Brain Health Fact Check
      • Cancer Related Fact Check
      • Child Care Fact Check
      • Dental and oral health fact check
      • Diabetes and metabolic health fact check
      • Diet and Nutrition Fact Check
      • Eye and ENT Care Fact Check
      • Fitness fact check
      • Gut health fact check
      • Heart health fact check
      • Kidney health fact check
      • Medical education fact check
      • Men's health fact check
      • Respiratory fact check
      • Skin and hair care fact check
      • Vaccine and Immunization fact check
      • Women's health fact check
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Abroad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Fact Check
    • Bone Health Fact Check
    • Brain Health Fact Check
    • Cancer Related Fact Check
    • Child Care Fact Check
    • Dental and oral health fact check
    • Diabetes and metabolic health fact check
    • Diet and Nutrition Fact Check
    • Eye and ENT Care Fact Check
    • Fitness fact check
    • Gut health fact check
    • Heart health fact check
    • Kidney health fact check
    • Medical education fact check
    • Men's health fact check
    • Respiratory fact check
    • Skin and hair care fact check
    • Vaccine and Immunization fact check
    • Women's health fact check
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Abroad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • Diabetes and Endocrinology
  • Diabetes and Endocrinology News
  • Treatment Gaps: GLP-1...

Treatment Gaps: GLP-1 RA Discontinuation Higher in Patients Without Type 2 Diabetes, Study Finds

Written By : Medha Baranwal |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2025-02-06T09:00:37+05:30  |  Updated On 6 Feb 2025 9:01 AM IST
Treating obesity and fertility in the era of GLP-1 receptor agonists
  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • Email

USA: A new study has highlighted significant trends in the use of dual-labeled GLP-1 receptor agonists among US adults with overweight or obesity, shedding light on discontinuation and reinitiation patterns. The findings indicate that a majority of individuals discontinue treatment within the first year, with notable differences observed based on the presence of type 2 diabetes.

"Individuals without type 2 diabetes were more likely to discontinue GLP-1 receptor agonist therapy compared to those with the condition. Moreover, they exhibited lower rates of reinitiation, suggesting potential barriers to sustained treatment," the researchers wrote in JAMA Network Open. "These disparities raise concerns about adherence to effective weight management therapies and their long-term impact on health outcomes."

While GLP-1 receptor agonists effectively promote weight reduction and metabolic improvements, their long-term success depends on consistent use. However, adherence remains challenging, and discontinuation and reinitiation patterns are poorly understood. To enhance patient adherence, healthcare providers may need to implement strategies such as better education on the benefits of sustained therapy, proactive management of side effects, and personalized treatment plans.

Against the above background, Patricia J. Rodriguez, Truveta Inc, Bellevue, Washington, and colleagues aimed to examine the rates and determinants of discontinuation and subsequent reinitiation of GLP-1 RAs in adults with overweight or obesity.

For this purpose, the researchers conducted a retrospective cohort study including 125,474 adults with overweight or obese who newly initiated treatment with a dual-labeled GLP-1 receptor agonist—liraglutide, semaglutide, or tirzepatide—between January 1, 2018, and December 31, 2023. Participants had a baseline body mass index of 27 or more, a recorded weight measurement within 60 days before initiation, and regular care in the prior year. Follow-up lasted up to two years for discontinuation assessment and an additional two years for reinitiation.

Patients were stratified by type 2 diabetes status. Discontinuation and reinitiation rates were estimated using Kaplan-Meier models. The sociodemographic factors, health conditions, weight changes, and gastrointestinal adverse events were analyzed using time-varying Cox proportional hazards regression models. Analyses were conducted separately for patients with and without type 2 diabetes.

Key Findings:

  • The study included 125,474 adults with a mean age of 54.4 years, of whom 65.4% were women. Among the participants, 61.0% had type 2 diabetes.
  • One-year discontinuation rates were higher for patients without type 2 diabetes (64.8%) than those with type 2 diabetes (46.5%).
  • Greater weight loss was linked to lower discontinuation rates, with a 1% reduction in weight lowering the hazard of discontinuation by 3.1% in patients with type 2 diabetes and 3.3% in those without.
  • Higher-income (>$80,000) was associated with a lower risk of discontinuation in patients with type 2 diabetes (HR: 0.72).
  • Moderate or severe gastrointestinal adverse events increased the risk of discontinuation (HR: 1.38 for patients with type 2 diabetes and 1.19 for those without).
  • Among 41,792 patients with available weight data at discontinuation, one-year reinitiation rates were lower for those without type 2 diabetes (36.3%) than those with type 2 diabetes (47.3%).
  • Weight regain of 1% after discontinuation was associated with an increased likelihood of reinitiation, with a 2.3% higher hazard in patients with type 2 diabetes and 2.8% in those without.

The study found that most adults with overweight or obesity discontinued GLP-1 RA therapy within a year, with significantly higher discontinuation and lower reinitiation rates among those without type 2 diabetes. Greater weight loss and higher income (in patients with type 2 diabetes) were linked to lower discontinuation, whereas weight regain after discontinuation was associated with a higher likelihood of reinitiation.

"Differences in access and insurance coverage for patients without type 2 diabetes may have contributed to these patterns. Inequities in access and adherence to effective treatments could further widen existing disparities in obesity management," the researchers concluded.

Reference:

Rodriguez PJ, Zhang V, Gratzl S, et al. Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity. JAMA Netw Open. 2025;8(1):e2457349. doi:10.1001/jamanetworkopen.2024.57349


JAMA Network Openglucagon-like peptide-1 receptor agonists (GLP-1 RAs)overweightobesitytype 2 diabetesdiscontinuation
Source : JAMA Network Open
Medha Baranwal
Medha Baranwal

    MSc. Biotechnology

    Dr. Kamal Kant Kohli
    Dr. Kamal Kant Kohli

    Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

    Show Full Article
    Next Story

    Editorial

    Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Breast Cancer - Dr Aditya Murali

    Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Breast Cancer...

    Aspirin in Primary Prevention- When to Consider?

    Aspirin in Primary Prevention- When to Consider?

    Featured image representing medico legal

    What's the Role of Expert Opinion in Medical Negligence?

    7- Point Discharge Protocol for AECOPD: Time to Inculcate in Practice

    7- Point Discharge Protocol for AECOPD: Time to Inculcate in Practice

    Aspirin Use in Women Aged 40-50 with Diabetes and Hypertension: Identifying the Ideal Candidates

    Aspirin Use in Women Aged 40-50 with Diabetes and Hypertension: Identifying the Ideal Candidates

    View All

    Journal Club Today

    Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Breast Cancer - Dr Aditya Murali

    Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Breast Cancer...

    View All

    Health News Today

    Health Bulletin 09/ May/ 2025

    Health Bulletin 09/ May/ 2025

    View All
    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok